NBC reports private payers deny GLP-1 coverage post-weight loss, creating post-stabilization cliff

NBC News reports private insurers are increasingly denying coverage for GLP-1 weight-loss drugs like Wegovy and Zepbound after patients achieve target weight loss. This creates a 'post-stabilization cliff' where maintenance therapy is no longer covered. The denials hinge on payer interpretations of medical necessity and clinical guidelines for chronic weight management. This mid-course coverage change will trigger patient complaints and require new prior authorization battles for continuing therapy. Practices with a high-volume weight management service should brief clinical and billing staff on this emerging denial pattern and prepare patient-facing materials.